Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality
Journal of Clinical Investigation · 01.05.2024 · 134 (9)
DOI: 10.1172/jci176640 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.05.2024. Verfasst von Jeremy P Gygi und 43 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: COVID-19, Severity of Illness Index. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
BACKGROUND Patients hospitalized for COVID-19 exhibit diverse clinical outcomes, with outcomes for some individuals diverging over time even though their initial disease severity appears similar to that of other patients. A systematic evaluation of molecular and cellular profiles over the full disease course can link immune programs and their coordination with progression heterogeneity. METHODS We performed deep immunophenotyping and conducted longitudinal multiomics modeling, integrating 10 assays for 1,152 Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study participants and identifying several immune cascades that were significant drivers of differential clinical outcomes. RESULTS Increasing disease severity was driven by a temporal pattern that began with the early upregulation of immunosuppressive metabolites and then elevated levels of inflammatory cytokines, signatures of coagulation, formation of neutrophil extracellular traps, and T cell functional dysregulation. A second immune cascade, predictive of 28-day mortality among critically ill patients, was characterized by reduced total plasma Igs and B cells and dysregulated IFN responsiveness. We demonstrated that the balance disruption between IFN-stimulated genes and IFN inhibitors is a crucial biomarker of COVID-19 mortality, potentially contributing to failure of viral clearance in patients with fatal illness. CONCLUSION Our longitudinal multiomics profiling study revealed temporal coordination across diverse omics that potentially explain the disease progression, providing insights that can inform the targeted development of therapies for patients hospitalized with COVID-19, especially those who are critically ill. TRIAL REGISTRATION ClinicalTrials.gov NCT04378777. FUNDING NIH (5R01AI135803-03, 5U19AI118608-04, 5U19AI128910-04, 4U19AI090023-11, 4U19AI118610-06, R01AI145835-01A1S1, 5U19AI062629-17, 5U19AI057229-17, 5U19AI125357-05, 5U19AI128913-03, 3U19AI077439-13, 5U54AI142766-03, 5R01AI104870-07, 3U19AI089992-09, 3U19AI128913-03, and 5T32DA018926-18); NIAID, NIH (3U19AI1289130, U19AI128913-04S1, and R01AI122220); and National Science Foundation (DMS2310836).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yale School of Medicine, New Haven, Connecticut, USA.
- The University of Texas at Austin, Austin, Texas, USA.
- UCSF, San Francisco, California, USA.
- La Jolla Institute for Immunology, La Jolla, California, USA.
- Centre for Heart Lung Innovation, University of British Columbia, Vancouver, Canada.
- Prevention of Organ Failure (PROOF) Centre of Excellence, Providence Research, Vancouver, British Columbia, Canada.
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- NCATS NIH HHS
- NIAAA NIH HHS
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Science Foundation
Zitieren
APA
Gygi, J. P., Maguire, C., Patel, R. K., Shinde, P., Konstorum, A., Shannon, C. P., Xu, L., Hoch, A., Jayavelu, N. D., Haddad, E. K., IMPACC Network, Reed, E. F., Kraft, M., McComsey, G. A., Metcalf, J. P., Ozonoff, A., Esserman, D., Cairns, C. B., Rouphael, N., …, & Guan, L. (2024). Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality. Journal of Clinical Investigation, 134(9). https://doi.org/10.1172/jci176640
Vancouver
Gygi JP, Maguire C, Patel RK, Shinde P, Konstorum A, Shannon CP, et al. Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality. Journal of Clinical Investigation. 2024;134(9). doi:10.1172/jci176640
BibTeX
@article{Gygi2024,
author = {Gygi, Jeremy P and Maguire, Cole and Patel, Ravi K and Shinde, Pramod and Konstorum, Anna and Shannon, Casey P and Xu, Leqi and Hoch, Annmarie and Jayavelu, Naresh Doni and Haddad, Elias K and IMPACC Network, IMPACC Network and Reed, Elaine F and Kraft, Monica and McComsey, Grace A and Metcalf, Jordan P and Ozonoff, Al and Esserman, Denise and Cairns, Charles B and Rouphael, Nadine and Bosinger, Steven E and Kim-Schulze, Seunghee and Krammer, Florian and Rosen, Lindsey B and van Bakel, Harm and Wilson, Michael and Eckalbar, Walter L and Maecker, Holden T and Langelier, Charles R and Steen, Hanno and Altman, Matthew C and Montgomery, Ruth R and Levy, Ofer and Melamed, Esther and Pulendran, Bali and Diray-Arce, Joann and Smolen, Kinga K and Fragiadakis, Gabriela K and Becker, Patrice M and Sekaly, Rafick P and Ehrlich, Lauren Ir and Fourati, Slim and Peters, Bjoern and Kleinstein, Steven H and Guan, Leying},
title = {Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {9},
doi = {10.1172/jci176640}
}
EUVIMED